Design, Synthesis and Biological Evaluation of 1,3,5-Triazine Derivatives Targeting hA1 and hA3 Adenosine Receptor. 2022

Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.

Adenosine mediates various physiological activities in the body. Adenosine receptors (ARs) are widely expressed in tumors and the tumor microenvironment (TME), and they induce tumor proliferation and suppress immune cell function. There are four types of human adenosine receptor (hARs): hA1, hA2A, hA2B, and hA3. Both hA1 and hA3 AR play an important role in tumor proliferation. We designed and synthesized novel 1,3,5-triazine derivatives through amination and Suzuki coupling, and evaluated them for binding affinities to each hAR subtype. Compounds 9a and 11b showed good binding affinity to both hA1 and hA3 AR, while 9c showed the highest binding affinity to hA1 AR. In this study, we discovered that 9c inhibits cell viability, leading to cell death in lung cancer cell lines. Flow cytometry analysis revealed that 9c caused an increase in intracellular reactive oxygen species (ROS) and a depolarization of the mitochondrial membrane potential. The binding mode of 1,3,5-triazine derivatives to hA1 and hA3 AR were predicted by a molecular docking study.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines
D043684 Receptor, Adenosine A3 A subtype of ADENOSINE RECEPTOR that is found expressed in a variety of locations including the BRAIN and endocrine tissues. The receptor is generally considered to be coupled to the GI, INHIBITORY G-PROTEIN which causes down regulation of CYCLIC AMP. Adenosine A3 Receptors,Adenosine A3 Receptor,A3 Receptor, Adenosine,A3 Receptors, Adenosine,Receptors, Adenosine A3
D043705 Receptor, Adenosine A2A A subclass of adenosine A2 receptors found in LEUKOCYTES, the SPLEEN, the THYMUS and a variety of other tissues. It is generally considered to be a receptor for ADENOSINE that couples to the GS, STIMULATORY G-PROTEIN. Adenosine A2A Receptor,Adenosine A(2A) Receptor,Adenosine A2A Receptors,A2A Receptor, Adenosine,A2A Receptors, Adenosine,Receptors, Adenosine A2A
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
January 2013, Chemical & pharmaceutical bulletin,
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
February 2008, Bioorganic & medicinal chemistry letters,
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
May 2023, International journal of molecular sciences,
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
January 2019, Chemical & pharmaceutical bulletin,
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
February 2015, ChemMedChem,
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
February 2017, European journal of medicinal chemistry,
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
January 2020, Bioorganic chemistry,
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
November 2013, Bioorganic & medicinal chemistry,
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
December 2020, Molecules (Basel, Switzerland),
Sujin Park, and Yujin Ahn, and Yongchan Kim, and Eun Joo Roh, and Yoonji Lee, and Chaebin Han, and Hee Min Yoo, and Jinha Yu
October 2019, European journal of medicinal chemistry,
Copied contents to your clipboard!